S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

TBPH Theravance Biopharma Inc

9.37

0.00 (0.00%)

Pre Market

Last Updated: 21:15:20

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Theravance Biopharma Charts.

Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Theravance Biopharma Charts.

Theravance Biopharma, Inc. News

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Monday 29 April 2024 (4 days ago) • PR Newswire (US)

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Wednesday 10 April 2024 (3 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Tuesday 27 February 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Theravance Biopharma to Participate in an Upcoming Investor Conference
Thursday 22 February 2024 (2 months ago) • PR Newswire (US)

Form 3 - Initial statement of beneficial ownership of securities
Saturday 17 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

More Theravance Biopharma, Inc. News Articles

S&P ASX 300 Metals and M...

Commonwealth Bank Of Aus...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions